I. INTRODUCTION
Adenosine 5'-monophospate-activated protein kinase (AMPK) is known as the enzyme response for energy homeostasis within cells [1] . AMPK is activated by phosphorylation on the conserved threonine 172 (thr172) residue of  subunit; catalyzed by kinases such as LKB1 and Ca 2+ /Calmodulin dependent kinase kinase [2] and [3] . High cellular AMP/ATP ratio may activate AMPK to suppress ATP consumption and promote ATP generation reactions [4] . Upon activation, AMPK activates catabolic pathways such as glycolysis, fatty acid oxidation, glucose uptake; inhibits anabolic pathways such as fatty acid/cholesterol synthesis, protein synthesis, gluconeogenesis [5] . In addition to the regulation of energy homeostasis, recent studies also revealed that AMPK might involve in modulating cellular stresses, such as inflammatory responses. Pharmacological AMPK activator,5-aminoimidazole-4-carboxamideribose (AICAR) has been demonstrated to suppress inflammation of macrophages, glia cells, microglial cells and neutrophils [6] - [8] . The anti-inflammatory function of AMPK activators in LPS-induced lung injury or autoimmune disease was also observed in animals [7] - [9] . Herein, we demonstrated a novel AMPK activator which attenuated high glucose induced inflammatory response in vascular endothelial cells. Vascular inflammation is a common pathophysiological response in diseases including atherosclerosis, hypertension, diabetes and myocardial infarction [10] and [11] . One of the hallmarks of vascular inflammation is the monocytes and blood vessel interaction mediated by adhesion molecules. Stimuli such as reactive oxygen species (ROS) and cytokines induce expression of adhesion molecules including intracellular adhesion molecule-1 (ICAM-1), vascular adhesion molecule-1 (VCAM-1) and endothelial selectin (Eselectin) in endothelial cells [12] - [14] . This up-regulation of adhesion molecules results in adhering of leukocytes to vascular endothelium and leads to endothelial dysfunction and tissue injury [15] . In the presence high glucose, endothelial cells also demonstrate similar inflammation phenotypes as aforementioned [16] . It has also been reported that high glucose condition induce the secretion of inflammatory cytokine, IL-6, in endothelia cells [17] .
In the present study, we investigated anti-vascular inflammatory effects of a novel AMPK activator, ENERGI-F704, on human umbilical vein endothelial cells (HUVECs). We investigated the effect of ENERGI-F704 on AMPK activation and cell viability. It was found that in HUVECs the high glucose induced expression of IL-6 as well as the monocyte adhesion can be decreased by ENERGI-F704 upon AMPK activation.
II. MATERIALS AND METHOD

A. Reagents
All reagents were purchased from Sigma (St. Louis, MO, USA) except where otherwise specified. Dulbecco's modified Eagle's medium (DMEM) and fetal bovine serum (FBS) were purchased from Invitrogen (Carlsbad, 
B. Cell Viability Assay
Cell viability was analyzed using XTT assay. Briefly, HUVECs were seeded in 96-well plates at 4× 10 5 cells/ml for 18 h and treated with various concentration of ENERGI-F704 or vehicle. After 24 h incubation, 50 l of XTT (2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) reagent was added. The plates were then incubated for 4 h at 37°C . The absorbance at 490 nm and 690 nm were measure using microplate reader.
C. Western Blot Assays
HUVECs were collected at indicated time point and were lysed using cell lysis buffer [10 mM Tris-HCl pH7.5, 150 mM NaCl, 1 mM EDTA, 0.5% Triton-X 100, 1×Protease inhibitor cocktail (Roche, Basel, Switzerland), 1× PhosSTOP phosphatase inhibitor cocktail (Roche, Basel, Switzerland)] for 30 min at 4°C, and then centrifuged at 15,000×g for 1 min. The equal amount of cell lysates were resolved by 10% SDS-PAGE and then transfer to Immobilon polyvinylidene difluoride (PVDF) membranes (Millipore, Bedford, MA, USA). Membranes were blocked with 5% bovine serum albumin (BSA) in PBS and incubated with an anti-phospho-AMPK (Thr172) antibody (1:2000, Cell signaling) or an anti-actin antibody (1:5,000; Cell signaling) at 4°C overnight followed by the corresponding secondary antibody for 1 h at room temperature (RT). Immunoreactive bands were detected by chemiluminescence (VisGlow TM , Visual Protein, Taipei, TW) and recorded using Kodak XAR-5 film (Rochester, NY, USA). The detected signals were scanned and then quantified using TotalLab Quant software (TotalLab).
D. Enzyme-linked Immunosorbent assay (ELISA)
Examiniation The level of secreted IL-6 in culture medium was determined by ELISA following manufacturer's instruction (R&D Systems, Minneapolis, MN, USA). Briefly, polyclonal rat anti-mouse cytokine antibodies were used as capturing antibodies, and biotinylated polyclonal rat anti-mouse cytokine antibodies were used for detection. Streptavidin-horseradish peroxidase and tetramethylbenzidine sulfonate were added as color indicators, and plates were read at 405 nm.
E. Monocyte-endothelial Cell Adhesion Assay
The monocyte adhesion assay was modified as describe [18] . Briefly, HUVECs were seeded in 6-well plates at 4× 10 5 cells/ml for 18 h and were stimulated with 10 ng/ml of TNF- for another 6 h in the present of ENERGI-F704 or compound C. Regular passaged THP-1 cells were incubated with 10M of Calcein AM (SigmaAldrich) at 37°C for 30 min. Calcein AM labeled cells were harvest by centrifugation (1,000×g, 5 min) and washed three times with PBS. The fluorescent THP-1 cells were re-suspended in medium and were added into stimulated HUVECs. After 30 min, nonadhering THP-1 cells were washed twice with PBS and THP-1 cells bound to HUVEC were analyzed with fluorescence microscopy.
III. RESULTS
A. ENERGI-F704 Treatment Has No Effect on HUVEC Viability
We first examined the cytotoxic effect of ENERGI-F704 on HUVECs using XTT assay. As shown in fig. 1 , ENERGI-F704 did not affect the HUVECs viability at 20M to 1200 M when compared with vehicle treated cells ( fig. 1) .
B. ENERGI-F704 Activates AMPK in HUVECs
In the experiment to determine whether ENERGI-F704 activates AMPK, various concentration of ENERGI-F704 or AICAR were added to HUVECs for 6 h and then assessed western blot analysis. As shown in fig. 2 , ENERGI-F704 activated AMPK in a dose-dependent manner as monitored by phosphorylation of AMPK. Cotreatment of compound C suppressed the AMPK phosphorylation induced by ENERGI-F704. compound C in DMEM containing 25 mM of glucose for 6 h. Cell lysates collected from each condition were used to determine the phosphorylation of AMPK using Western blot analysis.
C. ENERGI-F704 Inhibits the Induction of IL-6
It has been demonstrated that IL-6 increased adhesion molecules expression in endothelial cells and led to activate endothelial cells. To further evaluate the effect of ENERGI-F704 on high glucose induced IL-6 secretion, the level of IL-6 in medium was analyzed using ELISA assay. The same with previous reports, high glucose timedependently increased IL-6 secretion (Fig. 3) . ENERGI-F704 suppressed high glucose induced IL-6 secretion in dose-dependent manner. The IL-6 secretion in 600 M ENERGI-F704 treated cells was inhibited to 50% relative to that in vehicle treated cells in high glucose DMEM. 
D. ENERGI-F704 Inhibits High Glucose Induced
Monocyte Adhesion To further explore the functional significance of ENERGI-F704 to endothelial cells-monocytes interaction, we examined the adhesion of THP1 to high glucoseinduced HUVECs. HUVECs were treated with 25 mM glucose in the present of ENERGI-F704 or vehicle for 72 h. ENERGI-F704 significantly inhibited the monocytes adhesion (Fig.4) . The monocyte adhesion in 600M ENERGI-F704 treated cells was inhibited to 32% relative to that in vehicle treated cells in high glucose DMEM. More importantly, the inhibition of monocytes adhesion caused by ENERGI-F704 was fully blocked by AMPK inhibitor, compound C. 
IV. DISCUSSION
In the present study, we reported that ENERGI-F704 has significant anti-inflammatory activity in high glucose stimulated HUVECs. The western blot analysis showed that ENERGI-F704 dose-dependently increased AMPK phosphorylation in HUVECs suggesting that ENERGI-F704 is an AMPK activator (Fig. 2) . This result also supported by the increased phosphorylation of AMPK downstream targets such as ACC, TSC2, Raptor (data not shown). Extensive studies demonstrate AMPK is a repressor of inflammation but there are limited studies related to the effect of AMPK activators on high glucoseinduced vascular inflammation. We demonstrated herein that ENERGI-F704 suppressed high glucose induced IL-6 secretion and monocyte adhesion to HUVECs (Fig. 3 and  Fig. 4 ). ENERGI-F704 had no effect on HUVECs viability at 20 M to 1200 M (Fig. 1) , suggesting that the inhibitory effect on ENERGI-F704 in high glucose induced IL-6 secretion and monocyte adhesion is not caused by cytotoxic effect.
Hyperglycemia is considered the major factors for chronic inflammation in diabetes mellitus. The hyperglycemia enhances generation of reactive oxygen intermediates, inflammatory activation, and conducts endothelial dysfunction [19] and [20] . In diabetes patients, the level of IL-6 is much higher than that in normal glucose tolerance individuals. As the same with phenomenon in vivo, high glucose also increased IL-6 secretion in HUVECs (Fig. 3) . The increased IL-6 secretion of HUVECs might induce intercellular adhesion molecule 1 (ICAM-1) expression via STAT3 signaling cascade and enhance monocyte adhesion to endothelial cells [17] , [21] - [23] . In this study, we observed that the treatment of ENERGI-F704 resulted in a 50% decrease in IL-6 secretion, suggesting ENERGI-F704 may modulate high glucose induced monocyte adhesion.
Chronic vascular inflammation in diabetes may lead to cardiovascular diseases [10] - [24] . The earliest event of vascular inflammation is the monocyte adhesion to blood vessel. Several reports indicated that AMPK activators such as metformin and AICAR inhibited cytokine induced monocyte adhesion to endothelial cells [25] and [26] . We demonstrated herein ENERGI-F704 suppressed high glucose induced monocyte adhesion (Fig. 4) . More importantly, this inhibitory effect of ENERGI-F704 was fully blocked in the present of AMPK inhibitor, compound C, suggesting the suppression of monocyte adhesion by ENERGI-F704 was achieved via AMPK activation.
In conclusion, the present study demonstrates that a novel AMPK activator, ENERGI-F704, suppressed high glucose induced IL-6 secretion and monocyte adhesion to endothelial cells. ENERGI-F704 may have anti-vascular inflammatory activity and might be considered as potential drug for vascular inflammatory related diseases. 
